Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global, Pivotal, Placebo-Controlled Phase 2/3 Efficacy and Safety Study of WVE-210201 in Duchenne Muscular Dystrophy (DMD) Patients Amenable to Exon 51 Skipping

Trial Profile

A Global, Pivotal, Placebo-Controlled Phase 2/3 Efficacy and Safety Study of WVE-210201 in Duchenne Muscular Dystrophy (DMD) Patients Amenable to Exon 51 Skipping

Planning
Phase of Trial: Phase II/III

Latest Information Update: 06 Dec 2018

At a glance

  • Drugs WVE 210201 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Sponsors WaVe life Sciences
  • Most Recent Events

    • 06 Dec 2018 According to a WaVe life Sciences media release, study anticipates initiating in 2019.
    • 29 Aug 2018 New trial record
    • 09 Aug 2018 According to a WaVe life Sciences media release, this study will be powered to assess clinical efficacy and will include dystrophin expression readouts as part of interim and final analyses.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top